https://www.biospace.com/remegen-s-innovative-new-drug-telitacicept-rc18-obtains-positive-phase-iii-results-submitted-for-second-indication-for-treatment-of-rheumatoid-arthritis
RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently announced that...
new druginnovativetelitaciceptobtainspositive